Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Longitudinal assessment of ultrasound-guided complementary microRNA therapy of hepatocellular carcinoma.

Chowdhury SM, Lee T, Bachawal SV, Devulapally R, Abou-Elkacem L, Yeung TA, Wischhusen J, Tian L, Dahl J, Paulmurugan R, Willmann JK.

J Control Release. 2018 Jul 10;281:19-28. doi: 10.1016/j.jconrel.2018.05.009. Epub 2018 May 24.

PMID:
29758233
2.

CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.

Zeiner PS, Zinke J, Kowalewski DJ, Bernatz S, Tichy J, Ronellenfitsch MW, Thorsen F, Berger A, Forster MT, Muller A, Steinbach JP, Beschorner R, Wischhusen J, Kvasnicka HM, Plate KH, Stefanović S, Weide B, Mittelbronn M, Harter PN.

Acta Neuropathol Commun. 2018 Mar 1;6(1):18. doi: 10.1186/s40478-018-0521-5.

3.

Microbubble Enzyme-Linked Immunosorbent Assay for the Detection of Targeted Microbubbles in in Vitro Static Binding Assays.

Wischhusen J, Padilla F.

Ultrasound Med Biol. 2017 Jul;43(7):1506-1519. doi: 10.1016/j.ultrasmedbio.2017.03.004. Epub 2017 Apr 24.

PMID:
28450034
4.

High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma.

Weide B, Schäfer T, Martens A, Kuzkina A, Uder L, Noor S, Garbe C, Harter PN, Mittelbronn M, Wischhusen J.

J Invest Dermatol. 2016 Dec;136(12):2444-2452. doi: 10.1016/j.jid.2016.07.016. Epub 2016 Oct 2.

5.

Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.

Montalbán Del Barrio I, Penski C, Schlahsa L, Stein RG, Diessner J, Wöckel A, Dietl J, Lutz MB, Mittelbronn M, Wischhusen J, Häusler SFM.

J Immunother Cancer. 2016 Aug 16;4:49. doi: 10.1186/s40425-016-0154-9. eCollection 2016.

6.

The impact of breast cancer biological subtyping on tumor size assessment by ultrasound and mammography - a retrospective multicenter cohort study of 6543 primary breast cancer patients.

Stein RG, Wollschläger D, Kreienberg R, Janni W, Wischnewsky M, Diessner J, Stüber T, Bartmann C, Krockenberger M, Wischhusen J, Wöckel A, Blettner M, Schwentner L; BRENDA Study Group.

BMC Cancer. 2016 Jul 13;16:459. doi: 10.1186/s12885-016-2426-7.

7.

Impaired TGF-β induced growth inhibition contributes to the increased proliferation rate of neural stem cells harboring mutant p53.

Kumar P, Naumann U, Aigner L, Wischhusen J, Beier CP, Beier D.

Am J Cancer Res. 2015 Oct 15;5(11):3436-45. eCollection 2015.

8.

Functionally distinct patterns of nucleosome remodeling at enhancers in glucocorticoid-treated acute lymphoblastic leukemia.

Wu JN, Pinello L, Yissachar E, Wischhusen JW, Yuan GC, Roberts CWM.

Epigenetics Chromatin. 2015 Dec 2;8:53. doi: 10.1186/s13072-015-0046-0. eCollection 2015.

9.

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.

Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M.

Oncotarget. 2015 Dec 1;6(38):40836-49. doi: 10.18632/oncotarget.5696.

10.

Guidelines are advantageous, though not essential for improved survival among breast cancer patients.

Wolters R, Wischhusen J, Stüber T, Weiss CR, Krockberger M, Bartmann C, Blettner M, Janni W, Kreienberg R, Schwentner L, Novopashenny I, Wischnewsky M, Wöckel A, Diessner J.

Breast Cancer Res Treat. 2015 Jul;152(2):357-66. doi: 10.1007/s10549-015-3484-2. Epub 2015 Jun 24.

PMID:
26105798
11.

Human Parthenogenetic Embryonic Stem Cell-Derived Neural Stem Cells Express HLA-G and Show Unique Resistance to NK Cell-Mediated Killing.

Schmitt J, Eckardt S, Schlegel PG, Sirén AL, Bruttel VS, McLaughlin KJ, Wischhusen J, Müller AM.

Mol Med. 2015 Mar 23;21:185-96. doi: 10.2119/molmed.2014.00188.

12.

miRNAs can be generally associated with human pathologies as exemplified for miR-144.

Keller A, Leidinger P, Vogel B, Backes C, ElSharawy A, Galata V, Mueller SC, Marquart S, Schrauder MG, Strick R, Bauer A, Wischhusen J, Beier M, Kohlhaas J, Katus HA, Hoheisel J, Franke A, Meder B, Meese E.

BMC Med. 2014 Dec 3;12:224. doi: 10.1186/s12916-014-0224-0.

13.

Tumor suppressor p53 alters host cell metabolism to limit Chlamydia trachomatis infection.

Siegl C, Prusty BK, Karunakaran K, Wischhusen J, Rudel T.

Cell Rep. 2014 Nov 6;9(3):918-29. doi: 10.1016/j.celrep.2014.10.004. Epub 2014 Oct 30.

14.

MIF Receptor CD74 is Restricted to Microglia/Macrophages, Associated with a M1-Polarized Immune Milieu and Prolonged Patient Survival in Gliomas.

Zeiner PS, Preusse C, Blank AE, Zachskorn C, Baumgarten P, Caspary L, Braczynski AK, Weissenberger J, Bratzke H, Reiß S, Pennartz S, Winkelmann R, Senft C, Plate KH, Wischhusen J, Stenzel W, Harter PN, Mittelbronn M.

Brain Pathol. 2015 Jul;25(4):491-504. doi: 10.1111/bpa.12194. Epub 2014 Nov 20.

PMID:
25175718
15.

Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.

Roy R, Zurakowski D, Wischhusen J, Frauenhoffer C, Hooshmand S, Kulke M, Moses MA.

Br J Cancer. 2014 Oct 28;111(9):1772-9. doi: 10.1038/bjc.2014.462. Epub 2014 Aug 19.

16.

Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape?

Bruttel VS, Wischhusen J.

Front Immunol. 2014 Jul 29;5:360. doi: 10.3389/fimmu.2014.00360. eCollection 2014. Review.

17.

The TGF-β-inducible miR-23a cluster attenuates IFN-γ levels and antigen-specific cytotoxicity in human CD8⁺ T cells.

Chandran PA, Keller A, Weinmann L, Seida AA, Braun M, Andreev K, Fischer B, Horn E, Schwinn S, Junker M, Houben R, Dombrowski Y, Dietl J, Finotto S, Wölfl M, Meister G, Wischhusen J.

J Leukoc Biol. 2014 Oct;96(4):633-45. doi: 10.1189/jlb.3A0114-025R. Epub 2014 Jul 16.

PMID:
25030422
18.

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).

Diessner J, Bruttel V, Stein RG, Horn E, Häusler SF, Dietl J, Hönig A, Wischhusen J.

Cell Death Dis. 2014 Mar 27;5:e1149. doi: 10.1038/cddis.2014.115.

19.

The postreproductive salpingectomy.

Dietl J, Wischhusen J.

Fertil Steril. 2014 Mar;101(3):e20. doi: 10.1016/j.fertnstert.2013.12.020. Epub 2014 Feb 1. No abstract available.

PMID:
24491453
20.

Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.

Häusler SF, Del Barrio IM, Diessner J, Stein RG, Strohschein J, Hönig A, Dietl J, Wischhusen J.

Am J Transl Res. 2014 Jan 15;6(2):129-39. eCollection 2014.

21.

Lymphadenectomy in ovarian cancer--an overrated procedure?

Dietl J, Wischhusen J, Häusler SF.

BJOG. 2013 Sep;120(10):1297-8. doi: 10.1111/1471-0528.12358. No abstract available.

22.

Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells.

Diessner J, Bruttel V, Becker K, Pawlik M, Stein R, Häusler S, Dietl J, Wischhusen J, Hönig A.

Am J Cancer Res. 2013 Apr 3;3(2):211-20. Print 2013.

23.

Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis.

Krockenberger M, Kranke P, Häusler S, Engel JB, Horn E, Nürnberger K, Wischhusen J, Dietl J, Hönig A.

Anticancer Res. 2012 Dec;32(12):5233-8.

PMID:
23225421
24.

Whole miRNome-wide differential co-expression of microRNAs.

Stäehler CF, Keller A, Leidinger P, Backes C, Chandran A, Wischhusen J, Meder B, Meese E.

Genomics Proteomics Bioinformatics. 2012 Oct;10(5):285-94. doi: 10.1016/j.gpb.2012.08.003. Epub 2012 Aug 23.

25.

Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.

Hahne JC, Honig A, Meyer SR, Gambaryan S, Walter U, Wischhusen J, Häussler SF, Segerer SE, Fujita N, Dietl J, Engel JB.

Oncol Rep. 2012 Dec;28(6):2023-8. doi: 10.3892/or.2012.2041. Epub 2012 Sep 18.

PMID:
22992944
26.

The cancer stem cell subtype determines immune infiltration of glioblastoma.

Beier CP, Kumar P, Meyer K, Leukel P, Bruttel V, Aschenbrenner I, Riemenschneider MJ, Fragoulis A, Rümmele P, Lamszus K, Schulz JB, Weis J, Bogdahn U, Wischhusen J, Hau P, Spang R, Beier D.

Stem Cells Dev. 2012 Oct 10;21(15):2753-61. doi: 10.1089/scd.2011.0660. Epub 2012 Jul 16.

27.

Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.

Hassold N, Seystahl K, Kempf K, Urlaub D, Zekl M, Einsele H, Watzl C, Wischhusen J, Seggewiss-Bernhardt R.

Int J Cancer. 2012 Sep 15;131(6):E916-27. doi: 10.1002/ijc.27537. Epub 2012 Apr 4.

28.

High-sensitivity flow cytometry provides access to standardized measurement of small-size microparticles--brief report.

Robert S, Lacroix R, Poncelet P, Harhouri K, Bouriche T, Judicone C, Wischhusen J, Arnaud L, Dignat-George F.

Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):1054-8. doi: 10.1161/ATVBAHA.111.244616. Epub 2012 Feb 9.

29.

Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro.

Engel JB, Martens T, Hahne JC, Häusler SF, Krockenberger M, Segerer S, Djakovic A, Meyer S, Dietl J, Wischhusen J, Honig A.

Anticancer Drugs. 2012 Apr;23(4):426-36. doi: 10.1097/CAD.0b013e32834fb8ce.

PMID:
22314264
30.

The fimbria/ovarian surface junction.

Dietl J, Wischhusen J, Geissinger E.

Hum Reprod. 2011 Dec;26(12):3494-5; author reply 3495. doi: 10.1093/humrep/der337. Epub 2011 Oct 20. No abstract available.

PMID:
22016419
31.

TCR-dependent transformation of mature memory phenotype T cells in mice.

Wang X, Werneck MB, Wilson BG, Kim HJ, Kluk MJ, Thom CS, Wischhusen JW, Evans JA, Jesneck JL, Nguyen P, Sansam CG, Cantor H, Roberts CW.

J Clin Invest. 2011 Oct;121(10):3834-45. doi: 10.1172/JCI37210. Epub 2011 Sep 19.

32.

Toward the blood-borne miRNome of human diseases.

Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, Werner J, Hackert T, Ruprecht K, Huwer H, Huebers J, Jacobs G, Rosenstiel P, Dommisch H, Schaefer A, Müller-Quernheim J, Wullich B, Keck B, Graf N, Reichrath J, Vogel B, Nebel A, Jager SU, Staehler P, Amarantos I, Boisguerin V, Staehler C, Beier M, Scheffler M, Büchler MW, Wischhusen J, Haeusler SF, Dietl J, Hofmann S, Lenhof HP, Schreiber S, Katus HA, Rottbauer W, Meder B, Hoheisel JD, Franke A, Meese E.

Nat Methods. 2011 Sep 4;8(10):841-3. doi: 10.1038/nmeth.1682.

PMID:
21892151
33.

The post-reproductive Fallopian tube: better removed?

Dietl J, Wischhusen J, Häusler SF.

Hum Reprod. 2011 Nov;26(11):2918-24. doi: 10.1093/humrep/der274. Epub 2011 Aug 16. Review.

PMID:
21849300
34.

Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression.

Mittelbronn M, Platten M, Zeiner P, Dombrowski Y, Frank B, Zachskorn C, Harter PN, Weller M, Wischhusen J.

Acta Neuropathol. 2011 Sep;122(3):353-65. doi: 10.1007/s00401-011-0858-3. Epub 2011 Jul 21.

PMID:
21773885
35.

High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays.

Houben R, Hesbacher S, Schmid CP, Kauczok CS, Flohr U, Haferkamp S, Müller CS, Schrama D, Wischhusen J, Becker JC.

PLoS One. 2011;6(7):e22096. doi: 10.1371/journal.pone.0022096. Epub 2011 Jul 8.

36.

Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.

Häusler SF, Montalbán del Barrio I, Strohschein J, Chandran PA, Engel JB, Hönig A, Ossadnik M, Horn E, Fischer B, Krockenberger M, Heuer S, Seida AA, Junker M, Kneitz H, Kloor D, Klotz KN, Dietl J, Wischhusen J.

Cancer Immunol Immunother. 2011 Oct;60(10):1405-18. doi: 10.1007/s00262-011-1040-4. Epub 2011 Jun 3.

PMID:
21638125
37.

A specific miRNA signature in the peripheral blood of glioblastoma patients.

Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G, Weller M, Keller A.

J Neurochem. 2011 Aug;118(3):449-57. doi: 10.1111/j.1471-4159.2011.07307.x. Epub 2011 Jun 17.

38.

The forgotten fallopian tube.

Dietl J, Wischhusen J.

Nat Rev Cancer. 2011 Mar;11(3):227; author reply 227. doi: 10.1038/nrc2946-c1. No abstract available.

PMID:
21326326
39.

A cell-based luciferase-dependent assay for the quantitative determination of free extracellular adenosine with paracrine signaling activity.

Häusler SF, Ossadnik M, Horn E, Heuer S, Dietl J, Wischhusen J.

J Immunol Methods. 2010 Sep 30;361(1-2):51-6. doi: 10.1016/j.jim.2010.07.011. Epub 2010 Aug 5.

PMID:
20692262
40.

Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening.

Häusler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, Krockenberger M, Engel JB, Hönig A, Scheffler M, Dietl J, Wischhusen J.

Br J Cancer. 2010 Aug 24;103(5):693-700. doi: 10.1038/sj.bjc.6605833. Epub 2010 Aug 3.

41.

GDF-15 contributes to proliferation and immune escape of malignant gliomas.

Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, Tabatabai G, Wick W, Weller M, Wischhusen J.

Clin Cancer Res. 2010 Aug 1;16(15):3851-9. doi: 10.1158/1078-0432.CCR-10-0705. Epub 2010 Jun 9.

42.

Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers.

Engel JB, Schönhals T, Häusler S, Krockenberger M, Schmidt M, Horn E, Köster F, Dietl J, Wischhusen J, Honig A.

Arch Gynecol Obstet. 2011 Mar;283(3):603-10. doi: 10.1007/s00404-010-1457-6. Epub 2010 Apr 20.

PMID:
20405296
43.

Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: implications for lesion pathogenesis.

Heidbrink C, Häusler SF, Buttmann M, Ossadnik M, Strik HM, Keller A, Buck D, Verbraak E, van Meurs M, Krockenberger M, Mehling M, Mittelbronn M, Laman JD, Wiendl H, Wischhusen J.

Brain Behav Immun. 2010 Aug;24(6):975-84. doi: 10.1016/j.bbi.2010.04.003. Epub 2010 Apr 10.

PMID:
20385225
44.

Shigella mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression.

Galmbacher K, Heisig M, Hotz C, Wischhusen J, Galmiche A, Bergmann B, Gentschev I, Goebel W, Rapp UR, Fensterle J.

PLoS One. 2010 Mar 8;5(3):e9572. doi: 10.1371/journal.pone.0009572.

45.

Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin.

Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, Junker M, Oefner PJ, Bogdahn U, Wischhusen J, Spang R, Storch A, Beier CP.

Cancer Res. 2010 Mar 1;70(5):2030-40. doi: 10.1158/0008-5472.CAN-09-1707. Epub 2010 Feb 9.

46.

Macrophage migration inhibitory factor expression in cervical cancer.

Krockenberger M, Engel JB, Kolb J, Dombrowsky Y, Häusler SF, Kohrenhagen N, Dietl J, Wischhusen J, Honig A.

J Cancer Res Clin Oncol. 2010 May;136(5):651-7. doi: 10.1007/s00432-009-0702-5. Epub 2009 Nov 14.

PMID:
19915866
47.

Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.

Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC, Hönig A, Wischhusen J.

Cancer Res. 2009 Oct 15;69(20):8058-66. doi: 10.1158/0008-5472.CAN-09-0834. Epub 2009 Oct 13.

48.

Tubulin inhibitor AEZS 112 inhibits the growth of experimental human ovarian and endometrial cancers irrespective of caspase inhibition.

Engel JB, Schönhals T, Weidler C, Häusler S, Krockenberger M, Rieger L, Dietl J, Wischhusen J, Honig A.

Oncol Rep. 2009 Aug;22(2):361-7.

PMID:
19578778
49.

Stem cells, melanoma and cancer stem cells: the good, the bad and the evil?

Menaa F, Houben R, Eyrich M, Broecker EB, Becker JC, Wischhusen J.

G Ital Dermatol Venereol. 2009 Jun;144(3):287-96. Epub 2008 Dec 17. Review.

PMID:
19088701
50.

Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions.

Waschbisch A, Wintterle S, Lochmüller H, Walter MC, Wischhusen J, Kieseier BC, Wiendl H.

Arthritis Rheum. 2008 Nov;58(11):3600-8. doi: 10.1002/art.23997.

Supplemental Content

Loading ...
Support Center